Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.

Leukemia - 1 Jul 2014

Tefferi A, Lasho T L, Finke C M, Knudson R A, Ketterling R, Hanson C H, Maffioli M, Caramazza D, Passamonti F, Pardanani A

Abstract excerpt

Calreticulin (CALR) mutations were recently described in JAK2 and MPL unmutated primary myelofibrosis (PMF) and essential thrombocythemia. In the current study, we compared the clinical, cytogenetic and molecular features of patients with PMF with or without CALR, JAK2 or MPL mutations. Among 254...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin
Share to Chromosome Aberrations
Share to DNA Mutational Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression

Share to Janus Kinase 2

Share to Primary Myelofibrosis

Share to Prognosis

Share to Receptors, Thrombopoietin

Source

Identifiers

PMID: 24402162
DOI: 10.1038/leu.2014.3

Genes

CALR
JAK2
MPL
ASXL1
SRSF2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24402162-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.PMID 24402162Read ↗

Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosisSemantic proximity Read ↗

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.Semantic proximity Read ↗

Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.Semantic proximity Read ↗

JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.Semantic proximity Read ↗

CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.Semantic proximity Read ↗

An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.Semantic proximity Read ↗

The characteristics of CALR mutations in myeloproliferative neoplasms: a clinical experience from a tertiary care center in Qatar and a literature review.Semantic proximity Read ↗

From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.Semantic proximity Read ↗

Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisionsSemantic proximity Read ↗

Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.Semantic proximity Read ↗

JAK2, CALR, and MPL Mutations in Egyptian Patients With Classic Philadelphia-negative Myeloproliferative Neoplasms.Semantic proximity Read ↗

Calreticulin Mutations in Myeloproliferative NeoplasmsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.